Back | Next |
home / stock / immx / immx message board
Subject | By | Source | When |
---|---|---|---|
Pulled back | harry crumb | investorshub | 02/07/2023 11:02:46 PM |
We shall see where it goes, yes showed | harry crumb | investorshub | 02/04/2023 9:44:14 PM |
Nice and surprising close. | Laster | investorshub | 02/04/2023 2:35:57 AM |
2.50 is a load zone bigtime if she | harry crumb | investorshub | 02/03/2023 6:18:23 PM |
If this gets news an volumn, itl knock | harry crumb | investorshub | 02/03/2023 5:31:03 PM |
Rippn | harry crumb | investorshub | 02/03/2023 5:30:00 PM |
Gotta hold a core position an have patience. | harry crumb | investorshub | 02/01/2023 4:12:40 PM |
Stock trades horrible. | Laster | investorshub | 02/01/2023 3:52:37 PM |
Yes, 3$ next | harry crumb | investorshub | 02/01/2023 2:02:28 AM |
Finally broke $2.50. | Laster | investorshub | 01/31/2023 6:44:35 PM |
Itl bleed down again | harry crumb | investorshub | 01/27/2023 3:32:09 PM |
Mayb | harry crumb | investorshub | 01/27/2023 4:04:49 AM |
My guess tomorrow this explodes past $2.50. | Laster | investorshub | 01/27/2023 3:11:14 AM |
Big surge today up .46 on low volumn | harry crumb | investorshub | 01/24/2023 10:24:19 PM |
Got lucky that there was not enough volume | Laster | investorshub | 01/24/2023 2:56:06 PM |
MMs playing with the stock. | Laster | investorshub | 01/23/2023 8:41:16 PM |
Straight down after your call to load, and | 0whammies | investorshub | 01/18/2023 6:00:57 PM |
Load it now, thank us later. Patience is | harry crumb | investorshub | 01/18/2023 5:03:15 PM |
Looks weak. | Laster | investorshub | 01/18/2023 2:34:44 PM |
Didnt happen, back down showing 2.20 area, reload | harry crumb | investorshub | 01/08/2023 7:44:23 PM |
News, Short Squeeze, Breakout and More Instantly...
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced...
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of which 9 out of 12 were complete responders (75% CRs) 1 patient wi...